Welcome to our dedicated page for Brainsway news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway stock.
BrainsWay Ltd. reports developments in noninvasive neurostimulation treatments for mental health disorders. The company markets its proprietary Deep TMS platform, with FDA-cleared indications that include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, and derives revenue from leases and sales of Deep TMS systems.
Recurring updates include financial results, operating guidance, system placements, reimbursement and payer coverage for TMS therapy, clinical data for Deep TMS protocols such as SWIFT, and additional regulatory clearances. Company news also covers strategic minority-stake and milestone-based investments in mental health providers and related neurostimulation technologies, along with investor conference participation and operational updates across its U.S. and Israel-based business.
BrainsWay Ltd. announces positive coverage from Highmark BCBS for its Deep TMS™ treatment of obsessive-compulsive disorder (OCD), effective May 2, 2022. This coverage benefits 6.8 million members across New York, Pennsylvania, West Virginia, and Delaware. With existing coverage from Health Care Service Corporation, nearly 70 million lives are now eligible for Deep TMS OCD treatment. BrainsWay remains the only TMS company with FDA clearance for OCD, backed by positive clinical data. The firm aims to enhance reimbursement for Deep TMS through continued engagement with major payors.
BrainsWay Ltd. (NASDAQ: BWAY) reported a 30% year-over-year revenue growth in Q1 2022, achieving total revenues of $8.0 million, up from $6.1 million in Q1 2021. The company's gross margin improved to 77%, while operating expenses increased to $7.6 million, leading to an operating loss of $1.5 million. Despite operational challenges due to the Omicron surge, the firm saw a 21% increase in its Deep TMS installed base, totaling 790 systems as of March 31, 2022. Leadership changes were also made to support long-term growth.
BrainsWay Ltd. has appointed Eric Hirt as Vice President of U.S. Sales, bringing over 20 years of medical device sales and marketing experience. Hirt's role will focus on promoting the company's Deep Transcranial Magnetic Stimulation (Deep TMS™) system, aimed at expanding its market presence and increasing demand for its FDA-cleared treatment indications. The company highlights its commitment to advancing mental health solutions through innovative technology, backed by robust clinical evidence.
BrainsWay Ltd. (NASDAQ: BWAY) will showcase its Deep TMS™ technology for treating major depressive disorder at the Clinical TMS Society Annual Meeting in Chicago. An analysis of real-world data from 1,750 patients supports the efficacy of Deep TMS. The company aims to enhance noninvasive neurostimulation through innovative technologies and research. Alongside depression, BrainsWay's treatment includes indications for obsessive-compulsive disorder and smoking addiction. The company has multiple upcoming presentations at psychiatric conferences throughout May and June 2022.
BrainsWay Ltd. (NASDAQ: BWAY) announced it will report its first-quarter financial results and operational highlights on May 11, 2022, before U.S. markets open. The company will host a conference call at 8:30 AM ET to discuss the results and provide business updates. BrainsWay specializes in advanced noninvasive neurostimulation treatments for mental health disorders and is known for its FDA-cleared Deep Transcranial Magnetic Stimulation (Deep TMS™) technology, with indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.
BrainsWay Ltd. (NASDAQ: BWAY) appoints Dr. Joachim Seidel as the new Vice President of Corporate Development and Strategy, effective March 28, 2022. With over 20 years in the medical device sector, Dr. Seidel aims to drive strategic opportunities and enhance corporate development initiatives globally. His background includes leadership roles at Covidien, Medtronic, and PAREXEL, with a proven track record in market expansion and M&A. The company's focus on expanding its Deep TMS therapy aligns with its commitment to maximize stakeholder value.
BrainsWay Ltd. (NASDAQ: BWAY) announced a KOL webinar on Deep TMS™ Therapy for anxious depression set for March 22, 2022, at 10:30 am ET. KOL Shan H. Siddiqi, M.D. from Harvard Medical School will discuss the treatment landscape for anxious depression, where 60-90% of patients with major depressive disorder also experience anxiety. BrainsWay’s patented therapy is proven to reduce anxiety symptoms in depressed patients. Interested participants can register here.
BrainsWay Ltd. (NASDAQ: BWAY) reported a 34% revenue growth in 2021, reaching $29.7 million, compared to $22.1 million in 2020. Fourth-quarter revenues rose 20% to $8.5 million. The company improved its cash position to $57.3 million, reflecting positive operational cash flow. Notably, BrainsWay received a Local Coverage Determination from Medicare, expanding coverage for Deep TMS therapy to 60 million patients. Gross margins remained steady at 77%, while operating expenses increased to $8.0 million. The net loss for the year was $6.5 million.
Burlington, Mass., and Jerusalem, March 01, 2022 - BrainsWay Ltd. (NASDAQ: BWAY) announced that CEO Christopher von Jako, Ph.D., will present at the 32nd Annual Oppenheimer Healthcare Conference. The event will take place from March 15 to March 17, 2022, with BrainsWay's presentation scheduled for March 16 at 2:40 PM ET. The company specializes in noninvasive neurostimulation treatments for mental health disorders, including major depressive disorder and obsessive-compulsive disorder. Investors interested in meetings should contact their Oppenheimer representative.
BURLINGTON, Mass. and JERUSALEM, Feb. 28, 2022 – BrainsWay Ltd. (NASDAQ: BWAY) will report its fourth quarter and full year 2021 financial results on March 9, 2022, before U.S. markets open. A conference call and webcast, scheduled for 8:30 AM ET, will discuss the results and operational updates. BrainsWay is a leader in noninvasive neurostimulation for mental health, with FDA-cleared treatments for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The company aims to raise awareness and access to its Deep TMS technology, supported by robust clinical evidence.